Clinical support
Supporting healthcare professionals
More than just reliably delivering nutritional products, we’re also your clinical partner. This is why we’re always working to advance the understanding and add to the growing body of clinical evidence around human milk. We’re here with medical, clinical, economic, and research support.
Getting the most out of an EHMD
Talk to our clinical experts
Prolacta Clinical Advisory Board (PCAB)
We are a group of multidisciplinary, independent clinicians who are passionate about human milk science and nutrition. After witnessing first-hand the improved patient outcomes of an Exclusive Human Milk Diet (EHMD) with our patients, we work to enhance clinical practice, education, and outcomes for critically ill infants by sharing clinical expertise and emerging research.
Email: pcab@prolacta.com
Safely helping premature infants grow
A growing body of clinical evidence supports the use of an EHMD, including Prolacta’s 100% human milk–based fortifiers, as a new standard of care for premature infants born weighing ≤1250 g.1,2,3,4 Enhanced protocols with earlier fortification using Prolacta’s fortifiers have been associated with achieving adequate growth,3,5,6 improved lung health,2,3 a lower risk of complications,7,8,9 reduced healthcare costs,1,10 and shorter NICU stays1 for infants receiving an EHMD.
This latest study by lead author Robert Huston, MD, published in the Journal of Neonatal-Perinatal Medicine,3 found that fortification with Prolacta’s 100% human milk–based fortifiers in the first days of life improves growth and reduces the risk of BPD by 15% for infants receiving an EHMD, without the increased risk of complications seen with cow milk–based fortifiers.
The Huston et al (2020) early fortification study provides further data to support the practice of fortifying the human milk feedings of infants born at <1250 g birth weight with a 100% human milk–based fortifier at a lower feeding volume (<60 mL/kg/day) than has been a standard feeding practice in the past.